Signaling pathways
-
BA4592 BMS-587101Summary: BMS-587101 is a potent antagonist with oral activity. - BA4593 RO0270608Summary: RO0270608, the active metabolite of R411, is a dual integrin antagonist.
- BA4594 EfalizumabSummary: Efalizumab is a modulator that targets T cells and is a humanized monoclonal antibody to the LFA-1α subunit.
- BA4595 EMD527040Summary: EMD527040 is a potent and highly selective antagonist with antifibrotic activity.
- BA4596 SB-267268Summary: SB-267268 is a selective and non-peptide and integrin antagonist.
- BA4597 BMS-688521Summary: BMS-688521 is a potent, orally active interaction inhibitor.
- BA4598 ValategrastSummary: Valategrast (R-411freebase) is a potent orally active integrin and dual antagonist.
- BA4599 LDVSummary: LDV is a non-fluorescent analog of LDV-FITC.
- BA4600 ZalunfibanSummary: Zalunfiban (RUC-4) is a potent and selective platelet antagonist (=45nM).
- BA4601 RGD-4CSummary: RGD-4C is an arginine-glycine-aspartate peptide with integrin binding activity (ACDCRGDCFC).